Enhancement by hyperthermia of the in vivo antitumour effect of doxorubicin hydrochloride (DOX) and buthionine sulfoximine (BSO)-hydroxyapatite (HAP) complex

International Journal of Oncology

Volumn 10, Issue 5, 1997, Pages 961-964

  Imamura, Masato ^a   Seki, Toshihito ^a   Kunieda, Kouji ^a   Tamai, Toru ^a   Nishimura, Akira ^a   Inoue, Kyoichi ^a   Harada, Kazuki ^b  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b PL Gakuen Women's Junior College   (Japan)

Author keywords

buthionine sulfoximine; doxorubicin hydrochloride; drug delivery system; hydroxyapatite; hyperthermia; sarcoma 180

Indexed keywords

BUTHIONINE SULFOXIMINE; DOXORUBICIN; HYDROXYAPATITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; HISTOLOGY; HYPERTHERMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA;

EID: 0030915632     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.10.5.961     Document Type: Article

References (20)

1. Shiina S, Niwa Y, Shiratori Y, Terano A and Omata M: Percutaneous ethanol injection therapy for hepatocelluar carcinoma (Review). Int J Oncol 2: 669-675, 1993.
2. Scambia G, Benedettipanici P, Contu G, De Vincenzo R, Ferrandina G, Isola G, Maccio A and Mancuso S: Mechanisms and modulation of resistance to anthracyclines. Int J Oncol 4: 951-959, 1994.
3. Harada K: Development of new drug delivery system against hepatocellular carcinoma. PL Gakuen Women's Jr College Bull 18: 15-22, 1991.
4. Kunieda K, Seki T, Nakatani S, Wakabayashi M, Shiro T, Inoue K, Sougawa M, Kimura R and Harada K: Implantation treatment method of slow release anticancer doxorubicin containing hydroxyapatite (DOX-HAP) complex. A basic study of a new treatment for hepatic cancer. Br J Cancer 67: 668-673, 1993.
5. Dierickx PJ: Long-term buthionine-sulfoximine-mediated toxicity in cultured hepatoma cell lines. Res Commun Chem Pathol Pharm 67: 423-426, 1990.
6. Ford JM, Yang J and Hait WN: Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice. Cancer Res 51: 67-72, 1991.
7. Imamura M, Seki T, Kunieda K, Nakatani S, Inoue K, Nakano T and Harada K: Hydroxyapatite beads containing doxorubicin hydrochloride (DOX) and buthionine sulfoximine (BSO): a new anticancer drug design for local treatment with multiple drugs. Oncol Rep 2: 33-36, 1995.
8. Imamura M, Seki T, Kunieda K, Wakabayashi M, Inoue K, Obiya Y and Harada K: Antitumor effects of doxorubicin hydrochloride (DOX) and buthioninc sulfoximine (BSO)hydroxyapatite (HAP) complex on transplanted tumors in vivo. Oncol Rep 2: 509-511, 1995.
9. Imamura M, Seki T, Kunieda K, Nakatani S, Tamai T, Inouc K, Imamura M, Nagata K, Tanaka Y, Obiya Y and Harada K: Potential applicability of clinical hyperthermia using a Thermotron-RF8 as assessed from thermal distribution in an agar phantom containing hydroxyapatite. Oncol Rep 3: 1017-1019, 1996.
10. Kaplan EL and Meier P: Nonparametric estimation from incomplete observation. J Amer Statist Assn 53: 457-481, 1958.
11. Iwamiya T, Sawada S and Ohta Y: Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 33: S134-S138, 1994.
12. Kim BS, Yoo HS, Park YJ and Loh JJK: Current status and future aspects on treatment of liver cancer. Cancer Chemother Pharmacol 23: S118-S120, 1989.
13. Kim BS, Chung HC, Seong JS, Sun CO and Kim GE: Phase II trial for combined external radiotherapy and hyperthermia for unresectable hepatoma. Cancer Chemother Pharmacol 31: S119-S127, 1992.
14. Kusumoto T, Maehara Y, Sakaguchi Y, Kusumoto H and Sugimachi K: Azo-dye-induced primary hepatoma and a gradual increase in thermosensitivity. J Surg Oncol 42: 99- 102, 1989.
15. Maeta M, Kaibara N, Nakashima K, Kobayashi M, Yoshikawa T, Okamoto A and Sugiyama A: A case-matched control study of intrahepatoarterial chemotherapy in combination with or without regional hyperthermia for treatment of primary and metastatic hepatic tumors. Int J Hyperthermia 10: 51-58, 1994.
16. van Wijk R, Ovelgönne JH, Koning ED, Jaarsveld K, van Rijn J and Wiegant FAC: Mild step-down heating causes increased levels of HSP68 and of HSP84 mRNA and enhances thermotolerance. Int J Hyperthermia 10: 115-125, 1994.
17. Akuta K, Abe M, Kondo M, Yoshikawa T, Tanaka Y, Yoshida M, Miura T, Nakao N, Onoyama Y, Yamada T, Mukoujima T and Tsukada K: Combined effects of hepatic arterial embolization using degradable starch microspheres (DSM) in hyperthermia for liver cancer. Int J Hyperthermia 7: 231-242, 1991.
18. Yamada R, Tsuji K, Kishi K, Suwa K, Mitsuzane K, Tanaka K, Satoh M, Kawabata M and Maeda M: An attempt of hyperthermia with balloon catheter and immunochemotherapeutic agent. Radiat Med 6: 79-84, 1988.
19. Laskowitz DT, Elion GB, Dewhirst MW, Griffith OW, Cattley RC, Bigner DD and Friedman HS: Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion. Int J Hyperthermia 8: 111-120, 1992.
20. Laskowitz DT, Elion GB, Dewhirst MW, Griffith OW, Savina PM, Blum MR, Prescott DM, Bigner DD and Friedman HS: Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft. Radiat Res 129: 218-223, 1992.